Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis | Zendy

Serisier David J. | Zendy; Jones Graeme | Zendy; Tuck Andrew | Zendy; Connett Gary | Zendy; Carroll Mary P. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis

Author(s) -

Serisier David J.,

Jones Graeme,

Tuck Andrew,

Connett Gary,

Carroll Mary P.

Publication year - 2003

Publication title -

pediatric pulmonology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.866

H-Index - 106

eISSN - 1099-0496

pISSN - 8755-6863

DOI - 10.1002/ppul.10294

Subject(s) - medicine , sputum , cystic fibrosis , exacerbation , pseudomonas aeruginosa , antibiotics , antibiotic sensitivity , ceftazidime , intensive care medicine , respiratory failure , pathology , microbiology and biotechnology , tuberculosis , bacteria , biology , genetics

A 16‐year‐old male with cystic fibrosis (CF) was admitted to hospital with a severe infective exacerbation. Despite standard management, including conventionally selected intravenous antibiotics for Pseudomonas aeruginosa , chest physiotherapy, and institution of noninvasive ventilation (NIV) for progressive hypercapneic respiratory failure, he continued to deteriorate. Direct sputum sensitivity testing (DSST) revealed a novel combination of antibiotics that resulted in a rapid and remarkable clinical improvement. DSST is a form of “whole” sputum sensitivity testing that provides information on antibiotic synergy, and may more accurately reflect in vivo antibiotic sensitivity patterns in cystic fibrosis. Pediatr Pulmonol. 2003; 35:463–466. © 2003 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research